“Big pharma” is a shorthand term for the world’s largest pharmaceutical companies, typically used with a critical edge. While it literally refers to the handful of corporations that dominate global drug manufacturing, the phrase carries an implied accusation: that these companies prioritize profits over patients. The top 10 pharmaceutical firms each pull in more than $44 billion in annual revenue, and the term captures public skepticism about an industry that wields enormous financial and political power over healthcare.
Which Companies Count as Big Pharma
There’s no official list, but “big pharma” generally refers to the 15 to 20 largest drug companies by revenue. In 2024, Merck led the pack at $64.2 billion, followed closely by Pfizer at $63.6 billion. Johnson & Johnson, AbbVie, and AstraZeneca rounded out the top five, each exceeding $54 billion. Other familiar names include Roche, Novartis, Bristol Myers Squibb, Eli Lilly, and Sanofi.
Most of these companies are headquartered in the United States, though several are based in Switzerland, the UK, France, Denmark, Germany, and Japan. Together, the top 50 pharmaceutical firms generate hundreds of billions of dollars annually, making the industry one of the most profitable sectors in the global economy.
Why the Term Is Usually Negative
People rarely say “big pharma” as a neutral descriptor. The phrase implies that these companies use their size to charge high prices, influence lawmakers, and put shareholder returns ahead of public health. It’s the pharmaceutical equivalent of “big oil” or “big tobacco,” a label that frames the industry as a powerful interest group rather than a collection of healthcare innovators.
That framing didn’t appear out of nowhere. It grew from decades of high-profile controversies, from aggressive marketing of addictive painkillers to dramatic price hikes on life-saving medications. When people use the term, they’re usually pointing to a pattern: an industry that discovers genuinely important treatments but operates within a system that can make those treatments inaccessible or that rewards corporate strategy over patient benefit.
Profitability Compared to Other Industries
One reason “big pharma” sticks as a label is that pharmaceutical companies are significantly more profitable than most large corporations. A study published in JAMA compared 35 large drug companies with 357 other large public companies from 2000 to 2018. The pharmaceutical firms had a median net profit margin of 13.8%, compared to 7.7% for the broader market. That’s nearly double.
Even after controlling for company size and research spending, drug companies remained significantly more profitable. The gap narrowed somewhat in later years (2014 to 2018), but the overall trend held across nearly two decades of data. Critics point to these margins as evidence that drug pricing reflects market power, not just the cost of innovation.
Drug Prices in the United States
Nowhere is the “big pharma” debate louder than in the U.S. In 2022, American drug prices across all medications were roughly 2.78 times higher than prices in comparable countries. For brand-name drugs specifically, U.S. prices were at least 3.22 times higher, even after accounting for rebates and discounts.
A major reason for this gap: the U.S. is one of only two countries (along with New Zealand) that allows pharmaceutical companies to advertise prescription drugs directly to consumers on television and online. Most other nations ban this practice entirely. Canada permits a limited version where ads can mention either the drug’s name or the condition it treats, but not both. Direct-to-consumer advertising creates demand for expensive brand-name drugs, and critics argue it shifts prescribing decisions from doctors toward marketing departments.
Marketing Versus Research Spending
The pharmaceutical industry often defends high prices by pointing to the cost of developing new drugs, frequently cited at around $2.6 billion per drug brought to market. But spending data complicates that narrative. In 2004, the U.S. pharmaceutical industry spent $57.5 billion on promotion compared to $31.5 billion on research and development.
A 2015 analysis of the top 100 pharmaceutical companies by sales found that 64 of them spent at least twice as much on marketing and sales as on R&D. Forty-three spent five times as much, and 27 spent ten times more on marketing than on research. In Canada, where detailed company-level data was tracked from 2013 to 2016, between 8 and 10 out of 22 major companies spent more on promotion than on R&D in any given year. These figures are central to the “big pharma” critique: the industry frames itself as a research engine, but a large share of revenue goes toward convincing doctors and patients to choose one brand over another.
Patent Strategies and Drug Pricing
When a drug’s patent is about to expire, opening the door to cheaper generic versions, companies sometimes use a strategy called “evergreening.” This involves patenting minor modifications to an existing drug, such as a new coating, a different release mechanism, or a combination with another ingredient, to extend market exclusivity.
These modifications rarely offer meaningful therapeutic improvements. As one pharmaceutical policy researcher at York University put it, when a company evergreens a product, “you are not looking at any significant therapeutic advantage. You are looking at a company’s economic advantage.” The new version is essentially a sophisticated generic, tweaked just enough to qualify as a new invention. Brand-name companies build these lifecycle plans years in advance, timing the rollout of new versions to coincide with patent expiration on the old ones. The result is that patients and insurers keep paying brand-name prices for drugs that could otherwise be available as generics at a fraction of the cost.
Political Influence
The pharmaceutical and health products industry is consistently one of the biggest spenders on lobbying in the United States. In 2024, the sector reported $294 million in lobbying expenditures, nearly triple the $100 million spent in 2000. That money funds efforts to shape legislation on drug pricing, patent law, regulatory approval processes, and insurance coverage.
This spending is a core part of what people mean by “big pharma.” It’s not just the size of the companies or the price of the drugs. It’s the ability to influence the rules of the system itself, from how long a patent lasts to whether Medicare can negotiate prices.
Legal Settlements and Scandals
Several high-profile legal cases have reinforced the “big pharma” label. Johnson & Johnson faced an $8.9 billion settlement over product safety violations. Purdue Pharma, the maker of OxyContin, was hit with an $8.3 billion fraud penalty tied to its role in the opioid crisis. Johnson & Johnson also paid $5 billion for promoting medical products for uses not approved by regulators.
These aren’t isolated incidents. The pharmaceutical industry has paid tens of billions of dollars in fines and settlements over the past two decades for offenses ranging from fraudulent marketing to hiding safety data. For many people, these cases are the defining evidence behind the term: companies that broke the law, harmed patients, and treated the resulting fines as a cost of doing business.
What the Term Leaves Out
For all its critical weight, “big pharma” can flatten a complicated picture. The same companies that engage in aggressive pricing and lobbying also develop vaccines, cancer treatments, and therapies for rare diseases that smaller firms can’t afford to pursue. Drug development is genuinely expensive, risky, and slow, with most candidates failing before they ever reach patients.
The term also tends to treat the industry as a monolith when individual companies vary widely in their practices, pricing, and research focus. Some invest heavily in neglected diseases with limited profit potential. Others are more narrowly focused on blockbuster drugs in wealthy markets. “Big pharma” is a useful label for talking about systemic problems in the pharmaceutical industry, but it works better as a starting point for understanding those problems than as a complete explanation of them.